New mRNA bird flu vaccine shows promise in early trials

NCT ID NCT06382311

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new mRNA vaccine designed to protect against a potential pandemic of H5 bird flu. Nearly 1,000 healthy adults aged 18 to 85 received different doses to find the safest and most effective one. Researchers monitored side effects like pain, fever, and fatigue, and measured the immune response through blood tests. The goal is to have a ready vaccine if a bird flu outbreak ever becomes a global threat.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

avian influenza influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • GSK Investigational Site

    Anniston, Alabama, 36207, United States

  • GSK Investigational Site

    Little Rock, Arkansas, 72204, United States

  • GSK Investigational Site

    Fort Collins, Colorado, 80525, United States

  • GSK Investigational Site

    Fort Myers, Florida, 33912, United States

  • GSK Investigational Site

    West Palm Beach, Florida, 33409, United States

  • GSK Investigational Site

    Chamblee, Georgia, 30043, United States

  • GSK Investigational Site

    El Dorado, Kansas, 67042, United States

  • GSK Investigational Site

    Lenexa, Kansas, 66219, United States

  • GSK Investigational Site

    Lexington, Kentucky, 40509, United States

  • GSK Investigational Site

    Kansas City, Missouri, 64114, United States

  • GSK Investigational Site

    Omaha, Nebraska, 68144, United States

  • GSK Investigational Site

    Las Vegas, Nevada, 89102, United States

  • GSK Investigational Site

    Rochester, New York, 14609, United States

  • GSK Investigational Site

    Greensboro, North Carolina, 27405, United States

  • GSK Investigational Site

    Winston-Salem, North Carolina, 27103, United States

  • GSK Investigational Site

    Edmond, Oklahoma, 73013, United States

  • GSK Investigational Site

    Yukon, Oklahoma, 73099, United States

  • GSK Investigational Site

    Philadelphia, Pennsylvania, 19111, United States

  • GSK Investigational Site

    Austin, Texas, 78705, United States

  • GSK Investigational Site

    Norfolk, Virginia, 23502, United States

  • GSK Investigational Site

    Seattle, Washington, 98104, United States